1. Evaluation and characterization of Pd-Ag composite membrane fabricated by surfactant induced electroless plating (SIEP) for hydrogen separation. Issue 13 (2nd September 2019) Authors: Rahman, M. M.; Islam, M. S.; Rahman, M. A.; Tun, H.; Deshmane, V.; Hossain, T.; Ilias, S. Journal: Separation science and technology Issue: Volume 54:Issue 13(2019) Page Start: 2084 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES. (23rd June 2022) Authors: Joffe, E.; Nowakowski, G.; Tun, H.; Rosenthal, A.; Lunning, M.; Ramchandren, R.; Li, C.-C.; Zhou, L.; Martinez, E.; von Roemeling, R.; Earhart, R.; McMahon, M.; Isufi, I.; Leslie, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1011 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1298: THE IRAK-4 INHIBITOR EMAVUSERTIB (CA-4948) FOR THE TREATMENT OF PRIMARY CNS LYMPHOMA. (23rd June 2022) Authors: Von Roemeling, C.; Iqbal, M.; Doonan, B.; Hoang-Minh, L.; Klippel, K.; Tun, H.; Mitchell, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA. (23rd June 2022) Authors: Soussain, C.; Grommes, C.; Ward, R.; Peterson, C.; Cravets, M.; Mathias, A.; Sosa, J.; Kirby, B.; Ding, Z.; Yusuf, I.; Rose, M.; Steinberg, M.; Tun, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1967 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗